EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cytochrome P450–mediated metabolism of K31, a Ko143-derived ATP-binding cassette subfamily G member 2 inhibitor

Fu-Ying Qin, Junjie Zhu, Bjoern Brixius, Simone Brixius-Anderko, Jiaojiao Zhang, Meera Menon, Yixian Huang, Song Li, Xiaochao Ma

Drug Metabolism and Disposition · 2026-07 · 54 (7) · 100329

DOI: 10.1016/j.dmd.2026.100329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-07. Verfasst von Fu-Ying Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Heterocyclic Compounds, 4 or More Rings, Piperazines. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NIH NIGMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ko143 is a potent inhibitor of ATP-binding cassette subfamily G member 2, but its development is limited by poor metabolic stability due to rapid ester hydrolysis. To address this limitation, K31, an amide analog of Ko143, was recently developed. However, the metabolic profile of K31 in human liver microsomes (HLMs) remains suboptimal, and its underlying metabolic pathways are unclear. In this study, we systematically investigated the metabolism of K31 using HLMs, recombinant cytochrome P450 (P450) enzymes, chemical inhibition assays, and metabolomic analysis. Three P450-mediated metabolites of K31 were identified, with M1 as the predominant metabolite formed via O-demethylation. P450 phenotyping revealed that CYP2J2 and CYP4F3B contribute to M1 formation, an unusual finding given their primary roles in endobiotic metabolism and the predominantly extrahepatic expression of CYP2J2. Similar CYP2J2- and CYP4F3B-mediated O-demethylation pathways were also observed for Ko143 and its analog, K2. Chemical inhibition studies in HLMs further indicated that CYP4F3B plays a more prominent role than CYP2J2 in mediating O-demethylation of all 3 compounds, suggesting that this pathway is primarily driven by CYP4F3B in the liver and by CYP2J2 in extrahepatic tissues. Collectively, these findings provide new insights into the metabolism of Ko143 derivatives and inform the rational design of next-generation ATP-binding cassette subfamily G member 2 inhibitors with improved metabolic stability, reduced off-target metabolism, and minimized drug-endobiotic interactions. SIGNIFICANCE STATEMENT: This study highlights the central role of CYP4F3B in mediating the O-demethylation of Ko143 and its analogs in the liver. This study also identified a contribution from CYP2J2, the predominant cytochrome P450 isoform in the heart, suggesting potential extrahepatic metabolism of these compounds. These findings provide a foundation for the rational design of next-generation Ko143-derived ATP-binding cassette subfamily G member 2 inhibitors with enhanced metabolic stability, reduced off-target metabolism, and minimized drug-endobiotic interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 Enzyme SystemHeterocyclic Compounds, 4 or More RingsPiperazinesHumansMicrosomes, LiverAnimalsCytochrome P-450 CYP2J2Cytochrome P-450 Enzyme InhibitorsDiketopiperazines

Stichwörter der Autor:innen

ABCG2 inhibitorCYP2J2CYP4F3BK31Ko143O-demethylation

Substanzen

Cytochrome P-450 Enzyme System3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid…Heterocyclic Compounds, 4 or More RingsCytochrome P-450 CYP2J2CYP2J2 protein, humanPiperazinesCytochrome P-450 Enzyme InhibitorsDiketopiperazines

Autor:innen und Institutionen

  • Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: mxiaocha@pitt.edu.

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NIH NIGMS
  • NIDDK

Zitieren

APA

Qin, F. Y., Zhu, J., Brixius, B., Brixius-Anderko, S., Zhang, J., Menon, M., Huang, Y., Li, S., & Ma, X. (2026). Cytochrome P450–mediated metabolism of K31, a Ko143-derived ATP-binding cassette subfamily G member 2 inhibitor. Drug Metabolism and Disposition, 54(7), 100329. https://doi.org/10.1016/j.dmd.2026.100329

Vancouver

Qin FY, Zhu J, Brixius B, Brixius-Anderko S, Zhang J, Menon M, et al. Cytochrome P450–mediated metabolism of K31, a Ko143-derived ATP-binding cassette subfamily G member 2 inhibitor. Drug Metabolism and Disposition. 2026;54(7):100329. doi:10.1016/j.dmd.2026.100329

BibTeX
@article{Qin2026,
  author = {Qin, Fu-Ying and Zhu, Junjie and Brixius, Bjoern and Brixius-Anderko, Simone and Zhang, Jiaojiao and Menon, Meera and Huang, Yixian and Li, Song and Ma, Xiaochao},
  title = {Cytochrome P450–mediated metabolism of K31, a Ko143-derived ATP-binding cassette subfamily G member 2 inhibitor},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {7},
  pages = {100329},
  doi = {10.1016/j.dmd.2026.100329}
}
Kostenlos starten →